VRDN-002 is a humanized monoclonal antibody (mAb) targeting IGF1R/CD221. It is designed to reduce inflammation and exophthalmos associated with thyroid eye disease (TED). Additionally, VPI-2690B is utilized in research related to Graves ophthalmopathy.
Target:
IGF-1R
* VAT and and shipping costs not included. Errors and price changes excepted
